BioWorld

April 7, 2006

View Archived Issues

Tapestry Collects $25M For Lead Anticancer Compound

To move its lead cancer product into Phase II trials, Tapestry Pharmaceuticals Inc. closed a $25.5 million private placement with nine institutional investors. (BioWorld Today) Read More

Replidyne Files IPO For Up To $100M; Orapem Pending

Read More

Bioreactor To Bedside, Metastasis In Crosshairs

Read More

Aastrom Raising $25M For Adult Stem Cell Technology

Read More

Other News To Note

Read More

Clinic Roundup

Read More

U.S. Patent Disclosures

Read More